The use of fast gas chromatography-mass spectrometry (FGC-MS) was investigated to improve the efficiency of analysis of urine specimens that previously screened presumptively positive for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and/or 3,4 methylenedioxyethylamphetamine (MDEA) by immunoassay testing. Specimens were pretreated with basic sodium periodate, extracted using a positive-pressure manifold/cation-exchange solidphase cartridge methodology, and derivatized using 4-carbethoxyhexafluorobutyryl chloride (4-CB). The analytical method was compared to traditional GC-MS analysis and evaluated with respect to assay chromatography, linearity, sensitivity, precision, accuracy, and reproducibility. The limits of detection were 62.5 ng/mL for MDA and 31.25 ng/mL for AMP, MAMP, MDMA, and MDEA. All of the target analytes were linear to 12,000 ng/mL with the exception of MAMP which was linear to 10,000 ng/mL. The intra-assay precision of a 500 ng/m/multiconstituent control (n --15) ranged from 522.6 to 575.9 ng/mL with a coefficient of variation of less than 3.8%. Authentic human urine specimens (n --187) previously determined to contain the target analytes were re-extracted and analyzed by both FGC-MS and the currently utilized GC-MS method. No significant differences in specimen concentration were observed between these analytical methods. No interferences were seen when the performance of the FGC-MS method was challenged with ephedrine, pseudoephedrine, phenylpropanolamine, and
Introduction
Since the introduction of amphetamine (AMP) and methamphetamine (MAMP) in the 1930s, the abuse of these powerful central nervous system (CNS) stimulants has increased nationwide (1) . More recently, the recreational use of amphetamine designer drugs that possess both CNS stimulant and hallucinogenic properties has increased dramatically in the United States (2) . The concern that these drugs pose a serious threat to the mission, safety, and capability of the Armed Forces prompted the Department of Defense (DoD) to include 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in the panel of tested-for drugs in 1997 (3) .
At a July 2001 hearing of the Senate Governmental Affairs Committee concerning the problem of Ecstasy, the need for MDA testing of workers employed in safety-related and sensitive positions was recognized (4) . As a result of this recommendation, the Department of Health and Human Services (DHHS) proposed a change to the Federal Register to expand the confirmatory testing of amphetamines to include analyses for MDA, MDMA, and MDEA (5). For many laboratories, the increased workload associated with this proposed change will require a cost-effective method that incorporates simultaneous detection of AMP, MAMP, MDA, MDMA, and MDEA. Several methods have been published describing the simultaneous confirmation of AMP, MAMP, MDA, MDMA, and MDEA in human hair (6) and urine (7, 8) samples. An alternate and complimentary approach to further improving the efficiency of the confirmation process is the employment of fast gas chromatography coupled with mass spectrometry (FGC-MS). FGC was introduced to the United States market in 1999 (9) and purportedly offers the advantage of providing accurate and consistent data with a faster turn-around time than current chromatographic methodologies.
The purpose of the present study was the development of a rapid and sensitive FGC-MS method for the simultaneous determination of AMP, MAMP, MDA, MDMA, and MDEA in urine samples and the demonstration of the method's accuracy, precision, linearity, and reproducibility. This procedure was compared with our laboratory's current GC-MS method, and the ability of the FGC-MS method to produce forensically acceptable analytical results, according to current DoD and DHHS guidelines, was assessed.
Materials and Methods

Materials
Over-the-counter (OTC) drugs and pharmaceutical standards from the following classes (barbiturates, benzodiazepines, cocaine and cocaine metabolites, antidepressants, stimulants, hallucinogens, and opiates) were obtained from the Office of the Armed Forces Medical Examiner/Armed Forces Institute of Pathology (Rockville, MD), Alltech Associates, (Deerfield, IL), Sigma Chemical (St. Louis, MO), and International Chemical Nexus (Costa Mesa, CA). Analyte control materials were prepared in GC-MS-certified drug-free urine (Roche, Indianapolis, IN) using AMP, MAMP, MDA, MDMA, and MDEA purchased from Cerilliant (Round Rock, TX). Deuterated internal standard stocks (AMP-d n cat # A-016, MAMP-d]4 cat # M-092, MDA-ds cat# M-010, MDMA-d5 cat # M-011, and MDEA-d6 cat # M-081 were also purchased from Cerilliant). Structural positioning of the deuterium atoms are reflected in the vendor catalog (10) for the respective catalog numbers. Working stocks of internal standards were made up in methanol (Fisher Chemical, Fairlawn, N J).
Extraction
Extractions were done using a Speedisk | 48 positive-pressure extraction manifold (SPEware, San Pedro, CA) and polymerbased cation exchange/mixed-bed extraction columns (Cerex | CLIN II, 50-mg, 6-mL capacity). Methanol, ethyl acetate, chlorobutane, ammonium hydroxide, hydrochloric acid, sodium periodate, and sodium hydroxide were all ACS grade (Fisher Chemical, Pittsburgh, PA). The derivatizing reagent, 4-carbethoxyhexafluorobutyryl chloride (4-CB), was purchased from Lancaster Synthesis (Pelham, NH).
A mixture of the internal standard stock solution (0.01 mg/mL each), 2.0 mL of 1.0N NaOH, and 3.0 mL of 0.1M sodium periodate was added to 2 mL of urine pipetted into 50-mL plastic centrifuge tubes, and the contents were vortex mixed for 5 s. Tubes were capped and incubated for 15 rain at 50-60~ The samples were then allowed to cool at room temperature for 5 min prior to centrifugation at 2000 rpm. Periodate oxidation removes potential interference from over-the-counter medications/preparations containing pseudoephedrine and ephedrine (11) . The samples were poured into 6 mL Cerex | CLIN II columns and placed onto the Speedisk | apparatus. Positive pressure (2-3 standard cubic feet/h, 8CFH) was applied to load the columns. Next, 2 mL of distilled water was applied to the columns followed by 2 mL 0.1M HCl. Positive pressure (2-3 SCFH) was applied after the addition of each reagent, and then the columns were dried for 2-3 min at 25 psi. The columns were then washed with 2 mL of methanol and 2 mL of ethyl acetate. Positive pressure (2-3 SCFH) was applied after the addition of each reagent and the columns were dried for 2-3 rain at 25 psi. The target compounds were eluted by gravity flow into 10-mL conical glass tubes using 2.0 mL of freshly prepared ethyl acetate/ammonium hydroxide (98:2, v/v). Samples were evaporated to 50-100 IJL at room temperature under a stream of nitrogen gas. Evaporation to dryness was avoided to decrease the losses of analyte(s) by volatilization of the free bases.
Derivatization
Samples were derivatized using 200 ]~L of 4-CB in chlorobutane (1:]00, v/v). Samples were capped, mixed, and incubated in a 55-60~ water bath for 30 rain. The contents were mixed and incubated at 55-60~ for an additional 30 rain, followed by the addition of 0.3 mL of anhydrous ethanol. Samples were removed from the water bath, allowed to cool at room temperature, and then evaporated to 20-25 ]JL under a stream of nitrogen gas. Samples were reconstituted in 200 I~L of ethyl acetate and transferred to automated liquid sampler (ALS) vials for GC-MS analysis.
Analysis
All analyses were performed using an Agilent 6890N GC equipped with a 7683 autoinjector and a DB-5ms bonded-phase capillary column (15 m x 0.25-ram i.d., 0.25-pm film thickness), and coupled to a 5973N mass selective detector (Agilent, Palo Alto, CA). The standard GC-MS analytical method employed a 110 volt GC oven controller; whereas the fast GC-MS method used a 220 volt oven controller. The injection port was maintained at 255~ and oven conditions started at 154~ for 0.10 min followed by a 30~ ramp to 250~ and a 1.2 min terminal hold. All injections were split (split ratio of approximately 12:1) using helium as the carrier gas and a column pressure of approximately 16 psi. The transfer line was maintained at 290~ All analyses were performed in selected ion monitoring (SIM) mode using the ions indicated in Table I . The selected ion fragments are consistent by analogy with the fragmentation elucidated by Czarny and Hornbeck (12) and Stout et al. (8) . Ions were selected with these three considerations: 1. at least one ion must contain the aromatic ring to ensure the identity of the parent compound, 2. there must be minimum interference between the drug and internal standard in that the ions chosen for the internal standard should not appear in the drug ion chromatograms (and vice versa), and 3. the quantitation ratio should be 1.0 when equal amounts of drug and internal standard are co-extracted. TargetDB Thermo Lab Systems (Thermo Electron Corp, Waltham, MA), a GC-MS data analysis software program, was used to visualize and characterize ion chromatograms and to quantify the compounds of interest.
Calibration and controls
Analyte concentrations for specimens and controls were determined by single-point calibration using a multi-constituent calibrator containing 500 ng/mL each of AMP, MAMP, MDA, MDMA, and MDEA. The identification of each analyte was considered acceptable if the specimens and controls exhibited retention times within 2% and qualifier ion abundance ratios within 20% of the calibration standard. Each analytical batch contained the following multi-constituent controls: threshold (250 ng/mL), four-times cutoff control (2000 ng/mL), ephedrine/pseudoephedrine (500,000 ng/mL each), blind positive control (625 ng/mL), and blind negative control. With the exception of the negative blind control and the ephedrine/pseudoephedrine control, the acceptability criteria for these controls was quantitation within 20% of the expected concentrations. The negative blind control and ephedrine/pseudoephedrine control were required to test negative at less than the instrument's limit of detection (LOD), thereby demonstrating efficient and complete sodium periodate-mediated oxidation and structural disruption.
Results and Discussion
The total ion chromatogram of a calibrator containing 500 ng/mL each of AMP, MAMP, MDA, MDMA, and MDEA and their respective internal standards analyzed by traditional GC-MS is shown in Figure 1A . AMP, MAMP, MDA, MDMA, and MDEA were detected at approximate retention times of 4.1 min, 4.7 rain, 6.1 min, 6.7 rain, and 6.9 rain, respectively. In comparison, the same calibrator when analyzed by FGC-MS provided dramatic reductions in analyte retention times with AMP, MAMP, MDA, MDMA, and MDEA detected at approximate retention times of 1.8 min, 2.0 rain, 2.7 rain, 3.0 rain, and 3.1 rain, respectively ( Figure 1B) . The FGC-MS method reduced the overall single specimen analysis time from 8.5 to 4.0 rain. For an analytical batch containing 56 specimens the analysis time was reduced from 12.0 h to 7.25 h. The double peaks for AMP and MAMP in both chromatograms reflect separation of the deuterated internal standards from the undeuterated drugs. Solvent blanks were analyzed between all controls and samples to monitor for the presence of carryover; a requirement of the DoD Drug Testing program. Acceptance criteria for solvent * i
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Time (mln) blanks analyzed between authentic samples was that the drug and internal standard ions should be less than 10% of the corresponding peak height of the calibrator standard. No drug or internal standards peaks were visible above the noise level. Notably, a 1.2-min thermal hold was included post-ramp for column cleanup to remove potential sources of contamination. The chromatographic properties of the FGC-MS method provided narrow, baseline-resolved Gaussian-shaped peaks. Peak symmetry was automatically calculated using the Target data analysis software. The software package calculates the peak symmetry (Wb/W a) by setting a vertical line at the peak apex and then dividing the apical line to peak trailing edge distance at 10% peak height (Wb) by the peak leading edge to apical line distance at 10% peak height (Wa). Interassay symmetry calculations for the quantitation ion of the 250 ng/mL open control (12 Table VI separate batches) are detailed in Table II . All recorded peak symmetry measurements were within the laboratory's acceptance range of 0.5-2.0. The LOD and limit of quantitation (LOQ) for the FGC-MS method were determined by analyzing, in quadruplicate, three concentrations levels of samples spiked with AMP/MAMP/ MDA/MDMA/MDEA (31.25, 62.5 ng/mL, and 125 ng/mL). The LOD was set as the lowest concentration at which all replicates produced analyte qualifying ion ratios within 20% of the calibrator ratios. The LOQ was set as the lowest concentration at which the analyte qualifying ion ratios were within 20% of the calibrator determined ratios and the concentrations were within 20% of the expected concentrations. The LODs/LOQs were 62.5 ng/mL for MDA and 31.25 ng/mL for AMP, MAMP, MDMA, and MDEA (Table III) .
The upper limit of linearity (ULOL) was established by analyzing, in quadruplicate, samples spiked with AMP, MAMP, MDA, MDMA, and MDEA at 5000 ng/mL, 7500 ng/mL, 10,000 ng/mL, and 12,000 ng/mL until one or more of the qualifying ion ratios failed or the determined mean concentration for any analyte fell outside 15% of the expected concentration. The ULOL for MAMP was 10,000 ng/mL, and all of the other target analytes were linear to 12,000 ng/mL. The coefficient of variation for each drug replicate was less than 1.7%.
The precision of the FGC-MS method was evaluated by conducting intra-assay and interassay precision studies. The intraassay precision was assessed by analyzing 15 drug-free urine samples spiked with AMP/MAMP/MDA/MDMMMDEA at the calibrator concentration (500 ng/mL). The intra-assay precision for i
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. I . all five drugs ranged from 482.4 to 591.7 ng/mL with a coefficient of variation of less than 3.6% (Table IV) . The interassay precision was determined by the quantitation of the open low control (250 ng/mL) over the course of 12 separate analytical batches prepared over a two-month period. The inter-assay precision for the five drugs ranged from 230.8 to 262.6 ng/mL with a coefficient of variation less than 3.7% (Table V) . Chromatographic interference was investigated by assessing the potential for other compounds to co-elute with and possess common ions to the target analytes (or their internal standards), thereby interfering with the successful identification and quantitation of AMP, MAMP, MDA, MDMA, and/or MDEA. Multi-drug and single drug standards were prepared in certified drug-free urine at 10,000 ng/mL for 35 common over-thecounter and prescription drugs (including several drug metabolites), as well as other common drugs of abuse (Table VI) . These standards were analyzed both in the presence and absence of 200 ng/mL each of AMP, MAMP, MDA, MDMA, and MDEA. None of the 35 standards were found to interfere with any of the target analytes or their respective internal standards.
Potential assay interference was also determined for phentermine (50,000 ng/mL), phenylpropanolamine (50,000 ng/mL), ephedrine (50,000 ng/mL), and pseudoephedrine (1 mg/mL) prepared with and without 200 ng/mL each of the target analytes. Although these four compounds have structural and chemical properties similar to the target analytes, they did not interfere with the ability of the FGC-MS method to detect the presence of AMP, MAMP, MDA, MDMA, and/or MDEA. Retention times relative to AMP-du and MAMP-d14 for amphetamines, designer amphetamines, internal standards, and potential interferants (determined without periodate oxidation are listed in Table VII .
Comparative Study
A set of 187 authentic human urine specimens previously determined to contain AMP, MAMP, MDA, MDMA, and/or MDEA were used in this comparative study. These previously frozen samples were thawed, extracted, derivatized, and analyzed by the FGC-MS method as well as by the traditional GC-MS method. Figure 2 presents the linear regression analysis results for the FGC-MS analyses compared to the traditional GC-MS results. Specimens with values that exceeded the ULOL were diluted prior to extraction. The regression analyses and graphs show that the concentrations are in direct proportion. The resulting R 2 values ranged from 0.9978 to 0.0991, indicating excellent agreement between the two methods. Therefore, the FGC-MS method produces reproducible results that are comparable to those generated by the traditional GC-MS method currently used in our laboratory.
